Published in Biol Blood Marrow Transplant on February 06, 2010
Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res (2013) 1.26
Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy (2011) 1.11
NK cells in therapy of cancer. Crit Rev Oncog (2014) 0.96
Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer. Cancer J (2015) 0.94
Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions. Transfusion (2012) 0.94
NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis (2011) 0.86
NK cell-based immunotherapies in Pediatric Oncology. J Pediatr Hematol Oncol (2015) 0.85
Cytomegalovirus and tumors: two players for one goal-immune escape. Open Virol J (2011) 0.84
Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors. Cell Cycle (2016) 0.81
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells. Haematologica (2015) 0.80
Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A. Cancer Immunol Immunother (2015) 0.79
Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. J Biol Chem (2015) 0.78
Features of Memory-Like and PD-1(+) Human NK Cell Subsets. Front Immunol (2016) 0.76
Impact of the NK cell receptor LIR-1 (ILT-2/CD85j/LILRB1) on cytotoxicity against multiple myeloma. Clin Dev Immunol (2012) 0.76
Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia. Leuk Res Rep (2017) 0.75
Current perspectives on natural killer cell education and tolerance: emerging roles for inhibitory receptors. Immunotargets Ther (2015) 0.75
Leukocyte immunoglobulin-like receptors in human diseases: an overview of their distribution, function, and potential application for immunotherapies. J Leukoc Biol (2017) 0.75
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 12.75
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 11.81
Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature (2005) 7.40
Human natural killer cells. Blood (2008) 7.37
MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol (2005) 6.98
Human NK cell education by inhibitory receptors for MHC class I. Immunity (2006) 6.73
Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 3.88
Evolutionary struggles between NK cells and viruses. Nat Rev Immunol (2008) 3.79
Self-tolerance of natural killer cells. Nat Rev Immunol (2006) 3.75
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood (2005) 3.65
Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med (2003) 3.60
A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med (1997) 3.57
A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity (1997) 3.43
HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A (1998) 3.35
Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med (2006) 3.29
A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity (2005) 3.14
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant (2006) 2.93
Determinants of antileukemia effects of allogeneic NK cells. J Immunol (2004) 2.85
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood (2009) 2.75
MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood (2008) 2.71
Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood (2007) 2.36
Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood (2003) 2.08
NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood (2005) 1.78
KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood (2005) 1.74
The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur J Immunol (1999) 1.64
The CD94/NKG2-A inhibitory receptor complex is involved in natural killer cell-mediated recognition of cells expressing HLA-G1. J Immunol (1997) 1.58
Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2. Blood (2005) 1.58
A critical look at HLA-G. Trends Immunol (2008) 1.55
HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol (2001) 1.50
IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol (1999) 1.46
The leukocyte Ig-like receptor (LIR)-1 for the cytomegalovirus UL18 protein displays a broad specificity for different HLA class I alleles: analysis of LIR-1 + NK cell clones. Int Immunol (1999) 1.24
HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol (2001) 1.12
KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation. Mol Immunol (2005) 1.10
Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol (2003) 1.10
Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15. Exp Hematol (2008) 1.09
NK cell recognition of non-classical HLA class I molecules. Semin Immunol (2000) 1.05
A novel method for KIR-ligand typing by pyrosequencing to predict NK cell alloreactivity. Clin Immunol (2007) 0.96
HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum Immunol (2000) 0.93
Design of a flow cytometric assay for the determination of natural killer and cytotoxic T-lymphocyte activity in human and in different animal species. Cytometry (2000) 0.93
Analysis of the activating receptors and cytolytic function of human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation. Eur J Immunol (2004) 0.90
Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J Cell Mol Med (2008) 0.86
Flow cytometry of apoptosis. Curr Protoc Cell Biol (2004) 0.85
Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients. Leuk Res (2003) 0.84
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 7.28
Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood (2004) 7.09
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood (2007) 6.45
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (2010) 5.79
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood (2010) 4.46
Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood (2010) 4.02
Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood (2011) 3.66
Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood (2009) 3.62
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood (2003) 3.42
Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood (2008) 3.18
One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med (2014) 3.07
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant (2006) 2.93
Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood (2002) 2.79
Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood (2008) 2.53
A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood (2007) 2.39
Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood (2007) 2.36
Endoscopic robotic mitral valve surgery. J Thorac Cardiovasc Surg (2006) 2.35
Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med (2011) 2.14
Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant (2006) 2.14
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood (2005) 2.04
Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood (2002) 2.03
HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J Virol (2009) 2.03
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy (2010) 1.99
Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol (2012) 1.98
Thoracoscopic versus thoracotomy approaches to lobectomy: differential impairment of cellular immunity. Ann Thorac Surg (2008) 1.77
Natural killer-cell differentiation by myeloid progenitors. Blood (2010) 1.75
KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood (2005) 1.74
Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. Blood (2013) 1.72
Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood (2012) 1.67
Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J Immunol (2005) 1.67
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood (2013) 1.66
Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus. PLoS One (2010) 1.62
NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood (2011) 1.62
A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res (2003) 1.61
Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood (2009) 1.57
An Arabidopsis cell wall proteoglycan consists of pectin and arabinoxylan covalently linked to an arabinogalactan protein. Plant Cell (2013) 1.56
Immunological approaches to plant cell wall and biomass characterization: Glycome Profiling. Methods Mol Biol (2012) 1.56
Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood (2009) 1.51
Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood (2006) 1.51
Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion (2007) 1.49
Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother (2010) 1.42
The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood (2007) 1.39
Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). Biol Blood Marrow Transplant (2007) 1.39
Transformed large B-cell lymphoma in rituximab-allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumab. Leuk Lymphoma (2012) 1.39
Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood (2004) 1.38
Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol (2005) 1.35
Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant (2008) 1.35
Epigenetic control of highly homologous killer Ig-like receptor gene alleles. J Immunol (2005) 1.33
Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signaling. J Immunol (2011) 1.32
Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood (2010) 1.31
Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol (2006) 1.31
Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood (2009) 1.26
Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res (2013) 1.26
First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res (2007) 1.25
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med (2012) 1.23
Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res (2003) 1.22
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant (2010) 1.21
Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol (2014) 1.20
Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol (2009) 1.16
Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther (2012) 1.16
Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood (2011) 1.16
Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. Biol Blood Marrow Transplant (2009) 1.16